Comparison of Library of Plans with two daily adaptive strategies for whole bladder radiotherapy

Duncan den Boer a,*, Mariska D. den Hartogh a,1, Alexis N.T.J. Kotte a, Jochem R. N. van der Voort van Zyp a, Juus L. Noteboom a, Gijsbert H. Bol a, Thomas Willigenburg a, Anita M. Werensteijn-Honingh a, Ina M. Jürgenliemk-Schulz a, Astrid L.H.M.W. van Lier a, Petra S. Kroon a

a Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands

ARTICLE INFO

Keywords:
Bladder cancer
MR-guided radiotherapy
Daily online adaptive radiotherapy
Library of Plans

ABSTRACT

Background and purpose: Whole bladder radiotherapy is challenging due to inter- and intrafraction size and shape changes. To account for these changes, currently a Library of Plans (LoP) technique is often applied, but daily adaptive radiotherapy is also increasingly becoming available. The aim of this study was to compare LoP with two magnetic resonance imaging guided radiotherapy (MRgRT) strategies by comparing target coverage and volume of healthy tissue inside the planning target volume (PTV) for whole bladder treatments.

Methods and materials: Data from 25 MRgRT lymph node oligometastases treatments (125 fractions) were used, with three MRI scans acquired at each fraction at 0, 15 and 30 min. Bladders were delineated and used to evaluate three strategies: 1) LoP with two plans for a 15 min fraction, 2) MRgRT 15 min for a 15 min fraction and 3) MRgRT 30 min for a 30 min fraction. The volumes of healthy tissue inside and bladder outside the PTV were analyzed on the simulated post-treatment images.

Results: MRgRT 30 min had 120% and 121% more healthy tissue inside the PTV than LoP and MRgRT 15 min. For LoP slightly more target outside the PTV was found than for MRgRT 15 min and MRgRT 30 min with median 0% (range 0–23%) compared to 0% (0–20%) and 0% (0–10%), respectively.

Conclusions: Taking into account both target coverage and volume of healthy tissue inside the PTV, MRgRT 30 min performed better than LoP and MRgRT 15 min for whole bladder treatments. A 15 min daily adaptive radiotherapy workflow is needed to potentially benefit from replanning compared to LoP.

1. Introduction

Patients with muscle invasive bladder cancer typically have a five-year survival prognosis of about 50% [1]. Cystectomy has been the golden standard of treatment, but bladder sparing treatments involving radiotherapy have shown similar outcomes [1]. Bladder sparing treatments have the advantage of lower complication rates and improved quality of life by preserving normal bladder and sexual functions.

The wide variations in bladder size, shape and position have traditionally made it a challenging site for radiotherapy [2]. A commonly used bladder treatment strategy is the Library of Plans (LoP) strategy. Here, a “library” of planning target volumes (PTVs) and corresponding treatment plans is generated prior to treatment and the best fitting PTV is selected daily, typically based on an onboard conebeam CT (CBCT) [3–12]. For this approach it was shown that irradiated normal tissue volume and treatment margins could be reduced.

Another recent development in the field is the clinical availability of daily adaptive radiotherapy systems, CBCT-guided [13,14] as well as MR-guided systems [15–18]. These have already been shown suitable to deal with interfraction changes through daily adaptation of the treatment plan for several treatment sites and are therefore promising for bladder treatments. Vestergaard et al. have illustrated that MR-guided radiotherapy (MRgRT) has the potential to reduce irradiated normal tissue volume for bladder treatment [19] and both CBCT-guided [14] and MRgRT [20] have recently been demonstrated to be a feasible treatment modality for this tumor site. However, these studies were

* Corresponding author at: Department of Radiotherapy, Amsterdam University Medical Centers, De Boelelaan 1118, 1081 HV Amsterdam, the Netherlands.
E-mail address: d.denboer@amsterdamumc.nl (D. den Boer).

1 Radiotherapiegroep, Nico Bolkesteinlaan 85, 7416 SE Deventer, the Netherlands.

https://doi.org/10.1016/j.phro.2021.11.002
Received 25 March 2021; Received in revised form 10 November 2021; Accepted 10 November 2021
2405-6316/© 2021 The Authors. Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
done with a low number of bladder patients (three [14] and five [20]) and results were not compared to the current clinical practice, i.e. LoP.

Both strategies, LoP and daily adaptive radiotherapy, have their own advantages and disadvantages. A disadvantage of LoP is the chance that none of the PTVs generated prior to treatment is suitable for a specific daily situation. For daily adaptive RT the PTV is generated from the bladder of the day and the daily shape and volume can be taken into account. However, the treatment time with the presently available MRgRT systems from imaging to end of treatment delivery is typically a factor of two to three longer than the treatment time for a CBCT-based LoP strategy [5,16,20,21]. Consequently, relatively large PTV margins are needed to take into account the intrafraction filling of the bladder. Current margins reported for intrafraction changes of the bladder are typically for shorter time intervals (8–18 min) [8,11,18,21]. To speed up the daily MRgRT workflow technical developments are expected in the near future. Examples of these developments include faster auto-contouring [22] and Artificial Intelligence-assisted treatment planning reoptimization [23]. For daily adaptive CBCT-guided radiotherapy systems, times of 18 min from acceptance of first CBCT to start of irradiation have been reported for tumor sites in the pelvic region [14].

An advantage of MRgRT is the potential improvement of visualization of the soft tissues which can be taken into account with daily replanning to reduce the dose to the organs at risk (OAR). The possibility of intrafraction target monitoring and gating is also a reason to apply MRgRT [24].

The purpose of this study was to compare LoP with two daily adaptive MRgRT workflows with a total treatment time of 15 and 30 min per fraction, using clinically obtained MRgRT data. A retrospective analysis was performed to validate which strategy performs better in sparing healthy tissue and achieving target coverage. While our work focused on MRgRT, the conclusions are also relevant for CBCT-guided daily online adaptive radiotherapy.

2. Methods and materials

2.1. Patients

For the retrospective simulation, data from twenty-five lymph node metastases patients treated on a 1.5 T MR-linac (Unity, Elekta AB, Stockholm, Sweden) were used. This unique cohort was selected since bladder patients had not yet been treated with MRgRT in our institute. The included patients received clinical treatment with five fractions between August 2018 and August 2019. They provided written informed consent for use of their data as part of an ethics review board approved observational study. No specific driving instructions were provided.

2.2. Imaging data and delineation

For each patient a pre-treatment planning CT (0.9 x 0.9 x 2.0 mm³; Brilliance CT big bore, Philips Medical Systems, Best, NL) was used. Additionally, three MRI scans were acquired during each fraction on the MRgRT system, MRI1, MRI2 and MRI3, respectively (total N = 15 for each patient) [16]. MRI image acquisition time was median two minutes. For each patient a T1 or T2 sequence was selected for the MRgRT workflow by the radiation oncologist, based on tumor visibility assessed during a pre-treatment MRI session on a 1.5 T Philips Ingenia MRI scanner (Philips Medical Systems, Best, NL). For 19/25 treatments a 3D T1-weighted scan (reconstructed voxel size 0.8 x 0.8 x 1.0 mm³; FOV 400 x 400 x 300 mm³) was selected and for 6/25 treatments a 3D T2-weighted scan (reconstructed voxel size 0.6 x 0.6 x 2.0 mm³; FOV 400 x 400 x 300 mm³). The geometrical inaccuracy in and closely around the bladder is expected to be <0.7 mm for a 1.5 T MR-linac system [25].

The bladder was manually and retrospectively delineated on all CT and MRI images leading to BladderCT, Bladder1, Bladder2 and Bladder3.

2.3. Clinical MRgRT workflow

For each treatment fraction of the patient group mentioned above, daily online replanning was performed following the Adapt to Shape workflow of the Elekta Unity as described previously by Werenstein-Honingh et al. [16]. Each fraction, contours from the pre-treatment planning CT were propagated on the daily MRI using rigid and deformable registration.

Electron density was based on assignment to structures. If necessary, contours of GTV and OARs were manually adapted. The treatment plan, consisting of seven IMRT beams, was reoptimized for each fraction. A secondary dose calculation was performed with a separate treatment planning system, Oncentra version 4.5.2 (Elekta AB, Stockholm, Sweden). Irradiation was done with 7MV FFF. In the manuscript we will refer to this workflow as the “current” MRgRT workflow, illustrating the current capabilities of the MRgRT commercial system. The steps in this workflow are expected to take the same time for this patient group as for bladder patients [17,18]. As only a small part of the time is spent on irradiation [16], this time is not expected to change drastically when a different dose per fraction is given.

2.4. Simulated MRgRT approach

Two MRgRT daily optimization strategies were simulated: 1) a workflow based on the median time between MRI1 and MRI3 of 30 min (range 21–57 min), MRgRT15min, illustrating the current capabilities of an MRgRT commercial system and 2) a workflow, based on the median time between MRI1 and MRI3 of 15 min (range 8–25 min), MRgRT5min, illustrating a hypothetical optimized workflow (Fig. 1). For MRgRT15min all online adaptive steps including radiation delivery were assumed between MRI1 and MRI2 and for MRgRT15min these steps were between MRI1 and MRI3 (with the online adaptive steps between MRI1 and MRI2 and radiation delivery between MRI2 and MRI3 [16]).

PTVs were constructed from Bladder1 on MRI1 by population-based margins for MRgRT15min and MRgRT30min. Published data on margins are typically not validated for 30 min, but for shorter time intervals [8,11,19,26]. Therefore the margins to account for the intra-fraction bladder changes (intra-fraction patient motion, centroid motion and bladder filling) were constructed from the MRgRT dataset. To determine appropriate margins the delineated bladders on the MRI1 were asymmetrically expanded in six directions (left, right, anterior, posterior, inferior and superior) in steps of 1 mm until the delineated bladder on the MRI2 or MRI3 scan was completely encompassed for MRgRT30min and MRgRT15min strategy, respectively. Ten of the twenty-five patients were randomly selected. Population-based PTV margins were derived from these ten patients (N = 50 fractions). Margins were constructed for each direction by placing a 90% inclusion criterion on individual treatment fractions. The most commonly used margin recipe [27] uses 90% of patients instead of fractions, but in our case a new treatment plan would be generated for each fraction. This random selection and subsequent margin calculation was done to minimize bias and repeated 1000 times. Finally, the mean values were used for the analysis in this manuscript (see Supplementary Material A for more details).

2.5. Simulated LoP approach

The bladder was contoured on the planning CT and expanded to create two PTVs to fill the library. The expansion for PTV LoP Tight was 6/6 mm left/right, 10/10 mm ant/post and 6/10 mm inf/sup and for PTV LoP Wide: 10/10 mm left/right, 15/15 mm ant/post and 10/15 mm inf/sup. These values were based on literature [3,10] and clinical practice in our institute for CBCT-guided radiotherapy. The methodology is a further adaptation of the work as described previously by Willemse et al. [28]. Daily plan selection was based on the contoured bladder on MRI1, the smallest LoP PTV was selected that encompassed the complete bladder, named PTV LoP Selected. If the bladder on MRI1 did
would be asked to void the bladder or to drink additional liquid. Plan the analysis in line with clinical practice. In these cases, the patient the PTV in all directions except caudal), the fraction was not included in
selection and radiotherapy delivery were assumed between MRI
empty (if there was more than one cm distance between the bladder and
not fit completely within either of the LoP PTVs or if the bladder was too

dognot fit completely within either of the LoP PTVs or if the bladder was too
to drink additional liquid. Plan selection and radiotherapy delivery were assumed between MRI and MRI
empty (if there was more than one cm distance between the bladder and
not fit completely within either of the LoP PTVs or if the bladder was too

2.6. Treatment strategy evaluation and statistics

To evaluate the efficacy of the LoP and MRgRT approaches, the volume of healthy tissue in the PTV and the relative volume of the bladder outside the PTV were analyzed on the simulated post-treatment MRI images: MRI LoP and MRI LoP T15min. Volumes were determined with an in-house developed software package, Volumetool [31]. Fractions were only included in the statistical comparison when an LoP PTV was selected. The analysis we present was by pooling over the different scans for the patients. The differences in volumes between the strategies were tested by the two-tailed Wilcoxon matched-pairs signed-rank test; \( p < 0.05 \) was considered significant.

3. Results

Margins (mean ± standard deviation) for the two MRgRT strategies were 11 ± 2/17 ± 2 mm left/right, 24 ± 6/13 ± 2 mm ant/post and 36 ± 5/5 ± 1 mm sup/inf for MRgRT T15min and 8 ± 1/10 ± 1 mm left/right, 12 ± 2/11 ± 1 mm ant/post and 18 ± 2/4 ± 1 mm sup/inf for MRgRT T30min. The margins were asymmetric with the highest values for anterior and superior directions.

For the comparison of LoP vs. MRgRT strategies 107/125 fractions were included. For 7/125 fractions the PTV LoP Wide did not completely encompass the delineated bladder on MRI, and for 11/125 fractions the bladder was too empty. PTV LoP Tight and Wide were selected 73 and 34 times. The median and range of the bladder volumes at CT, MRI1, MRI2 and MRI3, as well as the PTVs for all three strategies are presented in Table 1. The median bladder filling speed was respectively 1.6 cm\(^3\)/min (range 0.3–12.0 cm\(^3\)/min) and 1.3 cm\(^3\)/min (range 0.1–9.3 cm\(^3\)/min) between MRI3 and MRI1, and MRI2 and MRI1.

| Structure | N [-] | Volume [cm\(^3\)] |
|-----------|-------|-------------------|
| Bladder   |       |                   |
| Planning CT | 25 | 97 (37–239) |
| MRI1 | 107 | 83 (31–284) |
| MRI2 | 125 | 83 (31–592) |
| MRI3 | 107 | 103 (46–411) |
| MRI1 | 125 | 104 (46–680) |
| MRI2 | 125 | 136 (53–570) |
| MRI3 | 125 | 136 (53–703) |
| PTV |       |                   |
| LoP Tight | 25 | 245 (105–438) |
| LoP Wide | 25 | 348 (164–581) |
| LoP Selected | 25 | 270 (105–546) |
| MRgRT T15min | 107 | 265 (134–620) |
| MRgRT T30min | 125 | 261 (134–1127) |
| MRgRT T30min | 107 | 466 (263–970) |
| MRgRT T30min | 125 | 462 (263–1046) |

1 Based on 107/125 fractions for which one of the two LoP plans was adequate for the observed bladder volume and patient would not be asked to void or drink.

For the MRgRT T30min workflow the volumes of the PTVs were up to 75% larger than for the other two strategies, with a median value of 466 cm\(^3\) compared to 270 cm\(^3\) for the selected LoP PTVs and 265 cm\(^3\) for the PTVs of MRgRT T15min.

The volumes of healthy tissue inside the PTV and target outside the PTV on the simulated post-treatment image are presented in Table 2. The median volume of healthy tissue inside the PTV was 332 cm\(^3\) for MRgRT T15min and corresponded to 71% of the PTV. This volume was significantly larger (\( p < 0.01 \)) than for MRgRT T30min and LoP with volumes of 151 and 150 cm\(^3\) respectively (Fig. 2a). For MRgRT T15min and LoP the volumes of healthy tissue inside the PTV did not significantly differ, \( p = 0.11 \).

The median value of target volume, i.e. bladder volume, outside the PTV on the simulated post-treatment image was 0.0 cm\(^3\) for all three methods (Fig. 2b). The MRgRT T15min strategy did not perform significantly better than the MRgRT T30min strategy, \( p = 0.39 \), however both
### Table 2

| Method | N  | Healthy tissue in PTV [cm³] | Missed target [cm³] | Missed target [%] |
|--------|----|----------------------------|---------------------|------------------|
| LoP   | 107 | 150 (28-299)               | 0 (0-48)            | 0 (0-23)         |
| MRgRT15min | 107 | 151 (59-260)               | 0 (0-28)            | 0 (0-10)         |
| MRgRT30min  | 125  | 151 (59-447)              | 0 (0-28)            | 0 (0-10)        |
| MRgRT30min  | 125  | 332 (136-537)             | 0 (0-100)           | 0 (0-20)        |

1. Based on 107/125 fractions for which one of the two LoP plans was adequate for the observed bladder volume and patient would not be asked to void or drink.

### 4. Discussion

To the best of our knowledge, this is the first study comparing LoP with MRgRT for whole bladder treatments using clinical MRgRT data. Two daily adaptive MRgRT strategies with a median time of 15 min, MRgRT15min and 30 min, MRgRT30min, between first image and end of treatment were compared to our clinically used LoP strategy. The MRgRT30min workflow had more healthy tissue inside the PTV than the LoP strategy. The MRgRT15min workflow had a similar volume of healthy tissue inside the PTV as LoP and missed less target.

Limitations of our study were the use of data of patients that did not have bladder cancer and the absence of a drinking protocol. The filling can be described as a “comfortably filled bladder”. However, the observed starting bladder volumes (median 97 cm³ at start of treatment) corresponded well with reported values of bladder patients with drinking protocols, with a range of 100–130 cm³ [6,7,11,19,32]. The bladder filling speed of median 1.6 cm³/min between MRI1 and MRI2 and 1.3 cm³/min between MRI1 and MRI3 were also in the range of reported values ranging from 0.8 to 2.1 cm³/min [26,32–35]. Even with a drinking protocol, large interpatient and interfraction variations typically still occur [33,34]. It has been shown that for empty and full bladder, the same values could be used in terms of margins [26,36].

The PTV margins found in this study for MRgRT15min strategy corresponded very well to margins reported in literature for studies with similar intrafraction time intervals [8,11,19,32], with values of 5–10/5–10 mm left/right, 8–14/9–14 mm ant/post and 13–33/5–6 mm sup/inf. The MRgRT15min margins fit well within the clinically used expansions for generating the LoP PTVs.

The PTV margins determined for the MRgRT30min workflow were relatively large, compared to other publications [6,8,11,19,20,26,36]. This was mostly due to the relatively long treatment time in comparison to the investigated time frames in other studies (8–18 min). In the study of Hunt et al. [20], the PTV margins (5/5 mm left/right, 15/10 mm ant/post and 15/5 mm sup/inf) covered 90% of the bladder at the 30 min time point, instead of the 100% for MRgRT30min in our study. The 75%–91% whisker in the boxplot, corresponding to 19 fractions was between 0.5 and 6.5% for LoP and 0.0–0.3% for MRgRT15min (Fig. 2c). The LoP strategy also showed outliers up to 21–23% of missed target volume, whereas the highest value for MRgRT15min was 10%. Some practical examples of bladder outside the PTV (missed target) are given in Fig. 3, where 17–28 cm³ and 100 cm³ of the target (bladder) were missed.

### Fig. 2

Simulated volume of healthy tissue inside PTV and missed target volume in post-treatment image (MRI2 for LoP and MRgRT15min, MRI3 for MRgRT30min) for whole bladder treatment using three treatment strategies MRgRT30min, MRgRT15min and LoP based on 25 treatments of 5 fractions. Data shown for 107 fractions (18 were excluded due to too full or too empty bladder filling for LoP). ** indicates significance of p < 0.01, by two-tailed Wilcoxon matched-pairs signed-rank test a) The volume of healthy tissue inside the PTV in the post-treatment image. b) The volume of bladder outside the PTV in the post-treatment image. c) Relative volumes of the bladder (in %) outside the PTV in the post-treatment image.

### Fig. 3

Two examples shown in the sagittal plane, illustrating exceptions; one or more of the strategies led to part of the bladder being outside the PTV in the simulated post-treatment image. Time of the image indicated in top right corner. a-d) Example 1. Planning CT (a) and T1 weighted images (b–d). The selected LoP PTV (yellow) was sufficient in MRI1, but missed a part (29 cm³) of the bladder in MRI2 (indicated by the yellow arrow in c). (e–h) Example 2. Planning CT (a) and T2 weighted images (f–h). The PTVs of all three strategies missed a part of the bladder in the simulated post-treatment MRI. For LoP and MRgRT15min 17 cm³ and 28 cm³ of the Bladder2 was outside the PTV respectively (indicated by the yellow arrow in g). For the MRgRT30min workflow: 100 cm³ of the Bladder3 was outside the PTV (indicated by the yellow arrow in h).
median intrafraction filling volume of the five patients studied in Hunt et al. [20], including one with a catheter, was 30 cm³ compared to 48 cm³ in our study.

The PTV margins of the MRgRT workflows were constructed from the same dataset as used for the comparison with LoP, this is a limitation of our study and could introduce bias for MRgRT30min and MRgRT15min. To mitigate this, margin construction was done with a repeated randomly selected subset of the patients and using the obtained mean values.

The advantage of the daily reoptimization using the MRgRT30min workflow compared to the LoP strategy was canceled out due to the needed relatively large population-based margins. The use of patient-specific margins could lead to a reduction in PTV volume and radiodensity on a predefined library. While this approach is in line with the results in this direction [8,37].

The workflow compared to the LoP strategy was canceled out due to the analysis could potentially introduce a bias for the LoP workflow. The difference between the LoP and MRgRT15min strategies in terms of target coverage and normal tissue in the PTV were small and bladder patients can be treated adequately with a CBCT-guided LoP strategy. However there are other advantages for using MRgRT. With the soft tissue contrast combined with daily adaptive radiotherapy, it has the potential to decrease toxicity of surrounding OARs [38]. In addition, the soft tissue contrast can visualize the tumor and allow a boost of this area without the need for implanted markers (which would be the case for CBCT-guided RT). MRgRT also allows for intrafraction monitoring and gating. In conclusion, MRgRT15min performed best, closely followed by LoP and then MRgRT30min for whole bladder treatments, taking into account the target coverage and the amount of healthy tissue inside the PTV. To be able to use MRgRT for whole bladder treatments including its functionalities, it is necessary to further optimize and accelerate the MRgRT workflow.

Conflict of Interest Notification

The overarching University Medical Center Utrecht MR-linac scientific project, including employment of one of the authors, has been partly funded by Elekta AB (Stockholm, Sweden). Elekta did not have any part in the design, execution or analysis of this study. The authors declared that there is no other conflict of interest.

Funding

None.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors want to acknowledge Simon Woodings for providing language help during the preparation of this manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jphro.2021.11.002.

References

[1] Arcangeli G, Arcangeli S, Srigiri A. L. A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MiBC). Crit Rev Oncol Hematol 2015;94:105–15. https://doi.org/10.1016/j.critrevonc.2014.11.007.

[2] Turner SL, Swindell R, Bowl N, Marrs J, Brooke B, Read G, et al. Bladder movement during radiotherapy for bladder cancer: implications for treatment planning. Int J Radiat Oncol Biol Phys 1997;39:355–60. https://doi.org/10.1016/S0360-3016(97)00709-9.

[3] Lalondrille S, Huddart R, Warren-Oseni K, Hansson VN, McNair H, Thomas K, et al. Adaptive-Predictive Organ Localization Using Cone-Beam Computed Tomography for Improved Accuracy in External Beam Radiotherapy for Bladder Cancer. Int J Radiat Oncol Biol Phys 2011;79:705–12. https://doi.org/10.1016/j.ijrobp.2009.12.003.

[4] Foroudi F, Wong J, Kron T, Rolfo A, Haworth A, Roxby P, et al. Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study. Int J Radiat Oncol Biol Phys 2011;81(3):765–71. https://doi.org/10.1016/j.ijrobp.2010.06.061.

[5] Meijer GJ, van der Toorn PP, Bal M, Schuring D, Weterings J, de Wildt M. High precision bladder cancer irradiation by integrating a library planning procedure of 6 prospectively generated SIB IMRT plans with image guidance using lipid marker. Radiat Oncol 2012;8:105:174–9. https://doi.org/10.1186/1748-717X-8-105.

[6] McDonald F, Lalondrille S, Taylor H, Warren-Oseni K, Khoo V, McNair HA, et al. Clinical Implementation of Adaptive Hypofractionated Bladder Radiotherapy for Improvement in Normal Tissue Irradiation. Clin Oncol (R Coll Radiol) 2013;25:549–56. https://doi.org/10.1016/j.clon.2013.06.001.

[7] Vestergaard A, Kallehaug JP, Petersen JB, Hayer M, Søndergaard J, Muren LP. An adaptive radiotherapy planning strategy for bladder cancer using deformation vector fields. Radiat Oncol 2014;11:2:571–5. https://doi.org/10.1186/1748-717X-11-2.

[8] Grenberg C, Vestergaard A, Hayer M, Søhn M, Pedersen EM, Petersen JB, et al. Intra-fractional bladder motion and margins in adaptive radiotherapy for urinary bladder cancer. Acta Oncol 2015;54(3):461–6. https://doi.org/10.3109/0284186X.2015.106238.

[9] Lutkenhaus LJ, Visser J, de Jong R, Hulshof MCC, Bel A. Evaluation of delivered dose for a clinical daily adaptive plan selection strategy for bladder cancer radiotherapy. Radiat Oncol 2015;11:51–6.

[10] Murphy V, Maslard R, Kalyani N, Mahantishtety U, Bakshi G, Prakash G, et al. Clinical Outcomes With Dose-escalated Adaptive Radiation Therapy for Urinary Bladder Cancer: A Prospective Study. Int J Radiat Oncol Biol Phys 2016;94:60–6. https://doi.org/10.1016/j.ijrobp.2015.09.010.

[11] Foroudi F, Pham D, Bressel M, Gill S, Kron T. Intrafraction bladder motion in radiotherapy estimated from pretreatment and posttreatment volumetric imaging. Int J Radiat Oncol Biol Phys 2016;83:867–72. https://doi.org/10.1016/j.ijrobp.2015.11.035.

[12] Collins SD, Leech MM. A review of plan library approaches in adaptive radiotherapy of bladder cancer. Acta Oncol 2018;57:566–73. https://doi.org/10.1080/0284186X.2017.1420908.

[13] Archambault V, Boylan C, Bullock D, Morgas T, Peltola J, Ruokokoski E, et al. Making on-Line Adaptive Radiotherapy Possible Using Artificial Intelligence and Machine Learning for Efficient Daily Re-Planning. Med Phys Int 2020;8:2077–86.

[14] Shibola P, Anderson JM, Calmef JC, Stierstrom D, Bongengen U, Geertzen P, et al. Clinical implementation of artificial intelligence-driven conebeam computed tomography-guided online adaptive radiotherapy in the pelvic region. Phys Imaging Radiat Oncol 2021;2:11–7. https://doi.org/10.1016/j.pirx.2020.12.004.

[15] Henke LE, Contreras JA, Green OL, Cai B, Kim H, Roach MG, et al. Magnetic Resonance Image-Guided Radiotherapy (MRgRT) A 4.5-Year Clinical Experience. Clin Oncol (R Coll Radiol) 2018;30:720–7. https://doi.org/10.1016/j.clon.2018.08.010.

[16] Wernesteijn-Honing AM, Kroon PS, Winkel D, Aalbers EM, van Asselen B, Bol GH, et al. Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases. Radiother Oncol 2019;134:50–4. https://doi.org/10.1016/j.radonc.2019.01.024.

[17] de Munck Keizer DM, Kerkmeijer LGW, Willigenburg T, van Lier ALHMW, Hartogh MDD, van der Voort van Zyp JRN, et al. Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac. Radiother Oncol 2020;151:88–94. https://doi.org/10.1016/j.radonc.2020.06.044.

[18] Tetar SU, Bruynzeel AME, Lagerwaard FJ, Slotman BJ, Roach MC, et al. The potential of MRI-guided online adaptive re-optimisation in radiotherapy of urinary bladder cancer. Radiother Oncol 2016;118:154–60. https://doi.org/10.1016/j.radonc.2015.11.003.

[19] Hunt A, Hanson I, Dunlop A, Barnes H, Bower L, Chick J, et al. Feasibility of Magnetic Resonance Guided Radiotherapy for the Treatment of Bladder Cancer. Clin Transl Radiat Oncol 2020;25:46–51. https://doi.org/10.1016/j.ctro.2020.09.002.
[21] Hafeez S, Warren-Oseni K, McNair HA, Hansen VN, Jones K, Tan M, et al. Prospective study delivering simultaneous integrated highdose tumor boost (≤70 Gy) with image guided adaptive radiation therapy for radical treatment of localized muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2016;94:1022–30. https://doi.org/10.1016/j.ijrobp.2015.12.379.

[22] Sharp G, Fritscher KD, Pekar V, Peroni M, Sivaramakrishna N, Veeraraghavan H, et al. Vision 20/20: perspectives on automated image segmentation for radiotherapy. Med Phys 2014;41:050902. https://doi.org/10.1118/1.4871620.

[23] Kontaxis C, Bol GH, Lagendijk JJW, Raaymakers BW. DeepDose: Towards a fast dose calculation engine for radiation therapy using deep learning. Phys Med Biol 2020;65:075013. https://doi.org/10.1088/1361-6560/ab7630.

[24] Mutic S, Dempsey JF. The ViewRay system: Magnetic Resonance-Guided and controlled radiotherapy. Semin Radiat Oncol 2014;24:196–9. https://doi.org/10.1053/j.semradonc.2014.02.008.

[25] Tijssen RHJ, Paulson ES, Glitzner M, Chugh B, Wetscherek A, et al. MRI commissioning of 1.5T MR-linac systems – a multi-institutional study. Radiother Oncol 2019;132:114–20. https://doi.org/10.1016/j.radonc.2018.12.011.

[26] Dees-Ribbers HM, Betgen A, Pos FJ, Witteveen T, Remeijer P, van Herk M. Inter- and intra-fractional bladder motion during radiotherapy for bladder cancer: A comparison of full and empty bladders. Radiother Oncol 2014;113:254–9. https://doi.org/10.1016/j.radonc.2014.08.019.

[27] Van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol 2004;14:52–64. https://doi.org/10.1053/j.semradonc.2003.10.003.

[28] Willems NW, Kroon PS, Boer JCI, Meijer GG, Zyp JRN, Noteboom JL. EP-1844: Clinical introduction of simple adaptive radiotherapy for transitional cell bladder carcinoma. Radiother Oncol 2017;105:5109. https://doi.org/10.1016/j.radonc.2018.04.019.

[29] Adil K, Popovic M, Cary FL, Faria SL, Ducklo M, Souhami L. Anisotropic bladder planning target volume in bladder radiation therapy. Pract Radiat Oncol 2019;9:24–8. https://doi.org/10.1016/j.prro.2018.07.006.

[30] Krishnan A, Tsang YM, Stewart-Lord A. The impact of intra-fractional bladder filling on ‘Plan of the day’ adaptive bladder radiotherapy. Tech Innov Patient Support Radiat Oncol 2019;9:931–4. https://doi.org/10.1016/j.tipsro.2019.01.001.

[31] Bol GH, Kotte ANTJ, van der Heide UA, Lagendijk JJW. Simultaneous multi-modality ROI delineation in clinical practice. Comput Methods Programs Biomed 2009;96:133–40. https://doi.org/10.1016/j.cmpb.2009.04.008.

[32] Mangar SA, Scruddle E, Huddart RA, Solhai SA, Horwich A, Dearmley DP, et al. Assessing intra-fractional bladder motion using cine-MRI as initial methodology for Predictive Organ Localization (POLO) in radiotherapy for bladder cancer. Radiother Oncol 2007;85:207–14. https://doi.org/10.1016/j.radonc.2007.04.037.

[33] McBain CA, Khoo VS, Buckley DL, Sykes JS, Green MM, Cowan RA, et al. Assessment of bladder motion for clinical radiotherapy practice using cine-magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009;75:664–71. https://doi.org/10.1016/j.ijrobp.2008.11.040.

[34] Sondergaard J, Olsen KO, Muren LP, Elstrem UV, Grau C, Heyer M. A study of image-guided radiotherapy of bladder cancer based on lipiodol injection in the bladder wall. Acta Oncol 2016;49:1109–15. https://doi.org/10.3109/02841861003789491.

[35] McBain CA, Green MM, Stratford J, Davies J, McCarthy C, Taylor B, et al. Ultrasound imaging to assess inter- and intra-fraction motion during bladder radiotherapy and its potential as a verification tool. Clin Oncol (R Coll Radiol) 2009;21:385–93. https://doi.org/10.1016/j.clon.2009.01.016.

[36] Wilson C, Mosesvili E, Tacey M, Quin I, Lawrentschuk N, Bolton D, et al. Assessment of intrafraction motion of the urinary bladder using magnetic resonance imaging (cineMRI). Clin Oncol (R Coll Radiol) 2020;32:101–9. https://doi.org/10.1016/j.clon.2019.09.056.

[37] Krywonos J, Fenwick J, Elkut F, Jenkinson I, Liu YH, Brunst JNH, et al. MRI image-based FE modelling of the pelvis system and bladder filling. Comput Methods Biomech Biomed Engin 2010;13:669–76. https://doi.org/10.1080/10255840903446961.

[38] Winkel D, Kroon PS, Werenstein-Honingsh AM, Bol GH, Raaymakers BW, Jürgenleitken-Schulz IM. Simulated dosimetric impact of online replanning for stereotactic body radiation therapy of lymph node oligometastases on the 1.5T MR-linac. Acta Oncol 2018;57:1705–12. https://doi.org/10.1080/0284186X.2018.1512152.